Ivabradine Reduces Digitalis-induced Ventricular Arrhythmias. 2017

Gerrit Frommeyer, and Jan Weller, and Christian Ellermann, and Nils Bögeholz, and Patrick Leitz, and Dirk G Dechering, and Simon Kochhäuser, and Kristina Wasmer, and Lars Eckardt
Division of Electrophysiology, Department of Cardiovascular Medicine, University of Münster, Münster, Germany.

The I(f) channel inhibitor ivabradine is recommended for treatment of heart failure but also affects potassium currents and thereby prolongs ventricular repolarization. The aim of this study was to examine the electrophysiological effects of ivabradine on digitalis-induced ventricular arrhythmias. Thirteen rabbit hearts were isolated and Langendorff-perfused. After obtaining baseline data, the digitalis glycoside ouabain was infused (0.2 μM). Monophasic action potentials and ECG showed a significant abbreviation of QT interval (-34 ms, p < 0.05) and action potential duration (APD90 ; -27 ms, p < 0.05). The shortening of ventricular repolarization was accompanied by a reduction in effective refractory period (ERP; -27 ms, p < 0.05). Thereafter, hearts were additionally treated with ivabradine (5 μM). Of note, this did not exert significant effects on QT interval (-4 ms, p = ns) or APD90 (-15 ms, p = ns) but resulted in an increase in ERP (+17 ms, p < 0.05). This led to a significant increase in post-repolarization refractoriness (PRR, +32 ms, p < 0.01) as compared with sole ouabain treatment. Under baseline conditions, ventricular fibrillation (VF) was inducible by a standardized pacing protocol including programmed stimulation and burst stimulation in four of 13 hearts (31%; 15 episodes). After application of 0.2 μM ouabain, eight of 13 hearts were inducible (62%, 49 episodes). Additional infusion of 5 μM ivabradine led to a significant suppression of VF. Only four episodes could be induced in two of 13 hearts (15%). In this study, ivabradine reduced digitalis-induced ventricular arrhythmias. Ivabradine did not affect ventricular repolarization in the presence of digitalis treatment but demonstrated potent anti-arrhythmic properties based on an increase in both ERP and PRR. The study further characterizes the beneficial electrophysiological profile of ivabradine.

UI MeSH Term Description Entries
D011817 Rabbits A burrowing plant-eating mammal with hind limbs that are longer than its fore limbs. It belongs to the family Leporidae of the order Lagomorpha, and in contrast to hares, possesses 22 instead of 24 pairs of chromosomes. Belgian Hare,New Zealand Rabbit,New Zealand Rabbits,New Zealand White Rabbit,Rabbit,Rabbit, Domestic,Chinchilla Rabbits,NZW Rabbits,New Zealand White Rabbits,Oryctolagus cuniculus,Chinchilla Rabbit,Domestic Rabbit,Domestic Rabbits,Hare, Belgian,NZW Rabbit,Rabbit, Chinchilla,Rabbit, NZW,Rabbit, New Zealand,Rabbits, Chinchilla,Rabbits, Domestic,Rabbits, NZW,Rabbits, New Zealand,Zealand Rabbit, New,Zealand Rabbits, New,cuniculus, Oryctolagus
D012032 Refractory Period, Electrophysiological The period of time following the triggering of an ACTION POTENTIAL when the CELL MEMBRANE has changed to an unexcitable state and is gradually restored to the resting (excitable) state. During the absolute refractory period no other stimulus can trigger a response. This is followed by the relative refractory period during which the cell gradually becomes more excitable and the stronger impulse that is required to illicit a response gradually lessens to that required during the resting state. Period, Neurologic Refractory,Periods, Neurologic Refractory,Refractory Period, Neurologic,Tetanic Fade,Vvedenskii Inhibition,Wedensky Inhibition,Inhibition, Vvedenskii,Inhibition, Wedensky,Neurologic Refractory Period,Neurologic Refractory Periods,Neuromuscular Fade,Neuromuscular Transmission Fade,Refractory Period, Neurological,Refractory Periods, Neurologic,Electrophysiological Refractory Period,Electrophysiological Refractory Periods,Fade, Neuromuscular,Fade, Neuromuscular Transmission,Fade, Tetanic,Neurological Refractory Period,Neurological Refractory Periods,Refractory Periods, Electrophysiological,Refractory Periods, Neurological,Transmission Fade, Neuromuscular
D002316 Cardiotonic Agents Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). Cardiac Stimulant,Cardiac Stimulants,Cardioprotective Agent,Cardioprotective Agents,Cardiotonic,Cardiotonic Agent,Cardiotonic Drug,Inotropic Agents, Positive Cardiac,Myocardial Stimulant,Myocardial Stimulants,Cardiotonic Drugs,Cardiotonics,Agent, Cardioprotective,Agent, Cardiotonic,Drug, Cardiotonic,Stimulant, Cardiac,Stimulant, Myocardial
D004071 Digitalis Glycosides Glycosides from plants of the genus DIGITALIS. Some of these are useful as cardiotonic and anti-arrhythmia agents. Included also are semi-synthetic derivatives of the naturally occurring glycosides. The term has sometimes been used more broadly to include all CARDIAC GLYCOSIDES, but here is restricted to those related to Digitalis. Glycosides, Digitalis
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004562 Electrocardiography Recording of the moment-to-moment electromotive forces of the HEART as projected onto various sites on the body's surface, delineated as a scalar function of time. The recording is monitored by a tracing on slow moving chart paper or by observing it on a cardioscope, which is a CATHODE RAY TUBE DISPLAY. 12-Lead ECG,12-Lead EKG,12-Lead Electrocardiography,Cardiography,ECG,EKG,Electrocardiogram,Electrocardiograph,12 Lead ECG,12 Lead EKG,12 Lead Electrocardiography,12-Lead ECGs,12-Lead EKGs,12-Lead Electrocardiographies,Cardiographies,ECG, 12-Lead,EKG, 12-Lead,Electrocardiograms,Electrocardiographies, 12-Lead,Electrocardiographs,Electrocardiography, 12-Lead
D006329 Heart Conduction System An impulse-conducting system composed of modified cardiac muscle, having the power of spontaneous rhythmicity and conduction more highly developed than the rest of the heart. Conduction System, Heart,Conduction Systems, Heart,Heart Conduction Systems,System, Heart Conduction,Systems, Heart Conduction
D000077550 Ivabradine A benzazepine derivative and selective HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CHANNELS inhibitor that lowers the heart rate. It is used in the treatment of CHRONIC STABLE ANGINA in patients unable to take BETA-ADRENERGIC BLOCKERS, and in the treatment of HEART FAILURE. 7,8-Dimethoxy-3-(3-(((4,5-dimethoxybenzocyclobutan-1-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-2H-benzazepin-2-one,Corlanor,S 16257,S 16257-2,S 16260-2,S-16257,S-16257-2,S-16260-2,S 16257 2,S 162572,S 16260 2,S 162602,S16257,S162572,S162602
D000200 Action Potentials Abrupt changes in the membrane potential that sweep along the CELL MEMBRANE of excitable cells in response to excitation stimuli. Spike Potentials,Nerve Impulses,Action Potential,Impulse, Nerve,Impulses, Nerve,Nerve Impulse,Potential, Action,Potential, Spike,Potentials, Action,Potentials, Spike,Spike Potential
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Gerrit Frommeyer, and Jan Weller, and Christian Ellermann, and Nils Bögeholz, and Patrick Leitz, and Dirk G Dechering, and Simon Kochhäuser, and Kristina Wasmer, and Lars Eckardt
October 1987, Archives internationales de pharmacodynamie et de therapie,
Gerrit Frommeyer, and Jan Weller, and Christian Ellermann, and Nils Bögeholz, and Patrick Leitz, and Dirk G Dechering, and Simon Kochhäuser, and Kristina Wasmer, and Lars Eckardt
January 1979, The Journal of pharmacology and experimental therapeutics,
Gerrit Frommeyer, and Jan Weller, and Christian Ellermann, and Nils Bögeholz, and Patrick Leitz, and Dirk G Dechering, and Simon Kochhäuser, and Kristina Wasmer, and Lars Eckardt
June 2013, Journal of molecular and cellular cardiology,
Gerrit Frommeyer, and Jan Weller, and Christian Ellermann, and Nils Bögeholz, and Patrick Leitz, and Dirk G Dechering, and Simon Kochhäuser, and Kristina Wasmer, and Lars Eckardt
January 1972, Giornale italiano di cardiologia,
Gerrit Frommeyer, and Jan Weller, and Christian Ellermann, and Nils Bögeholz, and Patrick Leitz, and Dirk G Dechering, and Simon Kochhäuser, and Kristina Wasmer, and Lars Eckardt
January 1970, Modern treatment,
Gerrit Frommeyer, and Jan Weller, and Christian Ellermann, and Nils Bögeholz, and Patrick Leitz, and Dirk G Dechering, and Simon Kochhäuser, and Kristina Wasmer, and Lars Eckardt
February 1978, European journal of pharmacology,
Gerrit Frommeyer, and Jan Weller, and Christian Ellermann, and Nils Bögeholz, and Patrick Leitz, and Dirk G Dechering, and Simon Kochhäuser, and Kristina Wasmer, and Lars Eckardt
March 1979, Archives des maladies du coeur et des vaisseaux,
Gerrit Frommeyer, and Jan Weller, and Christian Ellermann, and Nils Bögeholz, and Patrick Leitz, and Dirk G Dechering, and Simon Kochhäuser, and Kristina Wasmer, and Lars Eckardt
January 1969, European journal of pharmacology,
Gerrit Frommeyer, and Jan Weller, and Christian Ellermann, and Nils Bögeholz, and Patrick Leitz, and Dirk G Dechering, and Simon Kochhäuser, and Kristina Wasmer, and Lars Eckardt
June 1970, American heart journal,
Gerrit Frommeyer, and Jan Weller, and Christian Ellermann, and Nils Bögeholz, and Patrick Leitz, and Dirk G Dechering, and Simon Kochhäuser, and Kristina Wasmer, and Lars Eckardt
September 1981, Angiology,
Copied contents to your clipboard!